CYP2A6 rs162557: What Your Genotype Means
The rs162557 variant is located within the CYP2A6 gene, which encodes a primary enzyme responsible for breaking down nicotine in the body. This genetic variation is studied for its potential role in influencing how individuals metabolize nicotine and other substances processed by the same pathway.
What each genotype means
Normal nicotine metabolism
This genotype is associated with typical CYP2A6 enzyme activity levels. Individuals with this profile generally metabolize nicotine at a standard rate, though individual responses can vary based on other genetic and environmental factors. Please discuss any concerns regarding medication dosing or smoking cessation strategies with your clinician or pharmacist.
This is the most common genotype observed across most global populations.
Intermediate nicotine metabolism
This genotype may be associated with altered CYP2A6 enzyme activity compared to the most common profile. Research suggests that variations in this gene can influence how quickly nicotine is processed in the body, which may impact smoking behaviors or the effectiveness of certain medications. Please consult with your healthcare provider or pharmacist to discuss how this might relate to your specific health context.
This genotype is found at varying frequencies globally, with higher prevalence in certain populations where specific CYP2A6 variants are more common.
Reduced nicotine metabolism
This genotype is often associated with reduced CYP2A6 enzyme activity, which can lead to slower metabolism of nicotine and certain other drugs. Because this may affect how your body processes medications or responds to nicotine, it is important to discuss this finding with your clinician or pharmacist before making any changes to your health management.
This genotype is less common than the others and its frequency varies significantly by ancestry, being more frequently observed in specific populations.
Understanding the rs162557 Variant
The rs162557 variant is a single nucleotide polymorphism (SNP) situated in the CYP2A6 gene. In genomics, a SNP represents a change in a single building block of DNA, known as a nucleotide. The CYP2A6 gene provides instructions for creating the cytochrome P450 2A6 enzyme, which is primarily expressed in the liver. This enzyme is a critical component of the body's detoxification system, responsible for the metabolic inactivation of various compounds, including nicotine. Because rs162557 is located within this gene, researchers investigate whether this specific change alters the efficiency or expression of the enzyme. By studying such variants, scientists aim to understand why individuals process drugs and environmental chemicals at different rates, which can have implications for both pharmacology and behavioral health.
The Role of CYP2A6 in Metabolism
The CYP2A6 enzyme is the primary catalyst for converting nicotine into its major metabolite, cotinine. This metabolic process is a key factor in determining how long nicotine remains active in the bloodstream. Research has consistently shown that interindividual differences in the activity of this enzyme are largely driven by genetic polymorphisms. When the CYP2A6 enzyme functions at a high rate, nicotine is cleared from the body more quickly, which may influence how frequently a person feels the need to consume nicotine. Conversely, reduced enzyme activity can lead to slower nicotine clearance. Because CYP2A6 also plays a role in activating certain procarcinogens found in tobacco smoke, understanding these genetic variations is also relevant to broader studies on how the body handles toxic substances.
Research Associations and Evidence
The evidence linking CYP2A6 variants to nicotine metabolism is considered moderate and well-documented in scientific literature. Studies have observed that individuals with different CYP2A6 genotypes exhibit variations in their nicotine metabolite ratios, which serve as a marker for enzyme activity. While some variants are associated with differences in smoking intensity, such as the number of cigarettes smoked per day or the severity of withdrawal symptoms, the specific impact of rs162557 is part of a complex landscape of genetic influence. It is important to note that smoking behavior is multifactorial, influenced by a combination of genetic, environmental, and social factors. Therefore, while genetic associations provide valuable insights into biological predispositions, they do not act as a sole determinant of an individual's habits or health outcomes.
Population Frequency
The rs162557 variant is classified as a common polymorphism, meaning it appears frequently across diverse human populations. Genetic studies indicate that the distribution of CYP2A6 alleles can vary significantly between different ancestral groups, which contributes to the observed global differences in nicotine metabolism rates. Because this variant is common, it is frequently included in large-scale pharmacogenomic studies aimed at mapping how genetic diversity affects drug response. Researchers continue to analyze these frequency patterns to better understand the evolutionary history of the CYP2A6 gene and its ongoing impact on human health across different geographic regions.
Interpreting Your Genetic Information
Information regarding your genotype for rs162557 should be viewed as a piece of a much larger biological puzzle. While genetic research helps explain why people respond differently to nicotine or certain medications, it is not a diagnostic tool for predicting personal health outcomes or behavioral choices. You cannot use this information to self-diagnose or make medical decisions. If you are concerned about how your body processes medications or are seeking support for smoking cessation, it is essential to consult with a qualified clinician or pharmacist. These professionals can provide personalized guidance based on your full medical history and current clinical needs, ensuring that any decisions regarding your health are supported by comprehensive, evidence-based care.
How common is this variant?
The rs162557 variant is a common polymorphism found across various global populations, with genotype frequencies varying by ancestry.
Frequently asked questions
Does my CYP2A6 genotype determine if I will become a smoker?
No, genetics do not determine your behavior. While certain variants may influence how your body processes nicotine, smoking habits are complex and influenced by many environmental and social factors.
Can I use this genetic information to choose a smoking cessation aid?
You should not use genetic data to make medical decisions. Always discuss smoking cessation strategies and potential medication options with your doctor or pharmacist.
Is rs162557 the only variant that affects nicotine metabolism?
No, nicotine metabolism is influenced by multiple variants within the CYP2A6 gene and other genes. rs162557 is just one of many markers studied in this pathway.
Where can I find more information about my specific genetic results?
If you have received genetic testing results, you should review them with a genetic counselor or your primary healthcare provider. They can help you interpret the findings in the context of your overall health.
Sources & further reading
Educational information only, last refreshed 10/6/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs162557?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29